Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) - guidance (TA582)
- National Institute for Health and Care Excellence - NICE
- Publication date:
- 24 May 2019
NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults because Ipsen Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.